ES2173641T3 - Composicion de derivados opiaceos para la fabricacion de medicamentos. - Google Patents
Composicion de derivados opiaceos para la fabricacion de medicamentos.Info
- Publication number
- ES2173641T3 ES2173641T3 ES98956656T ES98956656T ES2173641T3 ES 2173641 T3 ES2173641 T3 ES 2173641T3 ES 98956656 T ES98956656 T ES 98956656T ES 98956656 T ES98956656 T ES 98956656T ES 2173641 T3 ES2173641 T3 ES 2173641T3
- Authority
- ES
- Spain
- Prior art keywords
- patient
- antinociceptive
- conjugate
- vivo
- introducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Utilización de una composición para la fabricación de un medicamento, constando dicha composición de un derivado de un opiáceo y análogos del mismo, caracterizada porque el derivado contiene un grupo funcional reactivo, que reacciona con grupos amino, grupos hidroxilo o grupos tiol de componentes de la sangre para formar enlaces covalentes estables, seleccionándose dicho grupo funcional reactivo entre N-hidroxi-succinimida, N-hidroxi-sulfo-succinimida y un grupo de maleimida, para aliviar el dolor o proporcionar un efecto analgésico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6470597P | 1997-11-07 | 1997-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2173641T3 true ES2173641T3 (es) | 2002-10-16 |
Family
ID=22057753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98956656T Expired - Lifetime ES2173641T3 (es) | 1997-11-07 | 1998-11-06 | Composicion de derivados opiaceos para la fabricacion de medicamentos. |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP1028971A2 (es) |
JP (2) | JP2001522817A (es) |
AT (2) | ATE216402T1 (es) |
AU (3) | AU1519799A (es) |
CA (2) | CA2301799C (es) |
DE (2) | DE69812727D1 (es) |
ES (1) | ES2173641T3 (es) |
IL (1) | IL135835A0 (es) |
WO (3) | WO1999024074A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6437092B1 (en) | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
AU748496B2 (en) * | 1998-03-23 | 2002-06-06 | Conjuchem, Inc. | Local delivery of long lasting therapeutic agents |
AU773891C (en) | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1264840B1 (en) | 1999-05-17 | 2009-09-23 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors of viral infection |
DK1105409T3 (da) * | 1999-05-17 | 2006-07-03 | Conjuchem Inc | Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US7144854B1 (en) | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
CA2373252C (en) * | 1999-05-17 | 2007-08-07 | Conjuchem Inc. | Long lasting anti-angiogenic peptides |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
JP2004520395A (ja) | 2001-02-02 | 2004-07-08 | コンジュケム,インコーポレーテッド | 長期持続性成長ホルモン放出因子誘導体 |
DE60226702D1 (de) | 2001-02-16 | 2008-07-03 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
DE60229677D1 (de) | 2001-05-31 | 2008-12-11 | Conjuchem Biotechnologies Inc | Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion |
US7927579B2 (en) | 2003-01-17 | 2011-04-19 | Advanced Proteome Therapeutics, Inc | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites |
DE602005022239D1 (de) | 2004-04-23 | 2010-08-19 | Conjuchem Biotechnologies Inc | Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten |
EP1773400A2 (en) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
WO2008047241A2 (en) | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
GB201204868D0 (en) | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
US20170158599A1 (en) * | 2014-07-18 | 2017-06-08 | Joseph D. Ceccoli | Compositions and methods comprising salicylates and polysalicylates |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59138958A (ja) * | 1983-01-31 | 1984-08-09 | Mitsubishi Chem Ind Ltd | 抗血清 |
US4784955A (en) * | 1984-09-21 | 1988-11-15 | Miles Inc. | Immunogen conjugates and the use thereof in a dihydropyridine assay |
IE901736L (en) * | 1989-05-17 | 1990-11-17 | Fuller H B Licensing Financ | Polypeptide-antibody conjugate for inhibiting cell adhesion |
DK608589D0 (da) * | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
JPH04364200A (ja) * | 1991-06-10 | 1992-12-16 | Unitika Ltd | 細胞接着性アルブミン |
US5399671A (en) * | 1992-11-18 | 1995-03-21 | Kluger; Ronald | Specifically crosslinked hemoglobin with free functionality |
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
-
1998
- 1998-11-06 ES ES98956656T patent/ES2173641T3/es not_active Expired - Lifetime
- 1998-11-06 WO PCT/US1998/023704 patent/WO1999024074A2/en active IP Right Grant
- 1998-11-06 WO PCT/US1998/023702 patent/WO1999024462A2/en not_active Application Discontinuation
- 1998-11-06 EP EP98957648A patent/EP1028971A2/en not_active Withdrawn
- 1998-11-06 WO PCT/US1998/023706 patent/WO1999024076A2/en active Application Filing
- 1998-11-06 AT AT98956656T patent/ATE216402T1/de not_active IP Right Cessation
- 1998-11-06 JP JP2000520159A patent/JP2001522817A/ja active Pending
- 1998-11-06 CA CA002301799A patent/CA2301799C/en not_active Expired - Fee Related
- 1998-11-06 EP EP98956656A patent/EP1007561B1/en not_active Expired - Lifetime
- 1998-11-06 DE DE69812727T patent/DE69812727D1/de not_active Expired - Lifetime
- 1998-11-06 AU AU15197/99A patent/AU1519799A/en not_active Abandoned
- 1998-11-06 AU AU13856/99A patent/AU1385699A/en not_active Abandoned
- 1998-11-06 DE DE69804974T patent/DE69804974T2/de not_active Expired - Lifetime
- 1998-11-06 CA CA002309205A patent/CA2309205A1/en not_active Abandoned
- 1998-11-06 IL IL13583598A patent/IL135835A0/xx unknown
- 1998-11-06 JP JP2000520470A patent/JP2001522863A/ja active Pending
- 1998-11-06 AT AT01121557T patent/ATE235513T1/de not_active IP Right Cessation
- 1998-11-06 AU AU13127/99A patent/AU750387B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
IL135835A0 (en) | 2001-05-20 |
WO1999024074A2 (en) | 1999-05-20 |
WO1999024076A9 (en) | 2000-06-08 |
DE69804974D1 (de) | 2002-05-23 |
ATE216402T1 (de) | 2002-05-15 |
DE69804974T2 (de) | 2002-11-07 |
AU1385699A (en) | 1999-05-31 |
CA2309205A1 (en) | 1999-05-20 |
AU1519799A (en) | 1999-05-31 |
AU750387B2 (en) | 2002-07-18 |
WO1999024076A2 (en) | 1999-05-20 |
EP1007561A2 (en) | 2000-06-14 |
CA2301799C (en) | 2007-08-07 |
EP1028971A2 (en) | 2000-08-23 |
WO1999024074A3 (en) | 1999-08-19 |
WO1999024462A2 (en) | 1999-05-20 |
ATE235513T1 (de) | 2003-04-15 |
CA2301799A1 (en) | 1999-05-20 |
EP1007561B1 (en) | 2002-04-17 |
AU1312799A (en) | 1999-05-31 |
DE69812727D1 (de) | 2003-04-30 |
JP2001522863A (ja) | 2001-11-20 |
JP2001522817A (ja) | 2001-11-20 |
WO1999024076A3 (en) | 1999-08-19 |
WO1999024462A3 (en) | 1999-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2173641T3 (es) | Composicion de derivados opiaceos para la fabricacion de medicamentos. | |
US20070082041A1 (en) | Topical delivery of codrugs | |
EP0740650A4 (en) | CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS | |
HU912442D0 (en) | Process for the production of medical preparations with continuous active agent release | |
NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
NL8403618A (nl) | Werkwijze voor het percutaan toedienen van metoclopramide. | |
BRPI0416028A (pt) | composto, conjugados do composto e de anticorpo-medicamento, composições farmacêuticas, usos dos conjugados, métodos para tratamento de cáncer, de uma doença auto-imune, de uma doença infecciosa e de um paciente, método para inibir a proliferação ou matar as células de tumor ou células cancerìgenas, método de inibição do crescimento de células de tumor, análise para detectar células de cáncer e artigo de manufatura | |
BR0016339A (pt) | Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto | |
WO1999056723A3 (en) | Hemoglobine-haptoglobin complexes for targeted drug delivery | |
WO2001060412A3 (en) | Modification of biopolymers for improved drug delivery | |
KR830002510A (ko) | 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물 | |
IL161670A0 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
PT1305057E (pt) | Composicao de biomateria microparticular para uso medicinal | |
AR002727A1 (es) | El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion. | |
DE60007074D1 (de) | Sulfatierte phosphatidylinositole, ihre herstellung und verwendung | |
ATE194498T1 (de) | Wasserfreies mittel auf lactulosebasis | |
IL117564A (en) | Pharmaceutical and diagnostic compositions containing lysine derivatives | |
ITMI960133A1 (it) | Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili | |
JPH05221862A (ja) | 坐剤用医薬組成物 | |
RU2002100065A (ru) | Применение верапамила и производных верапамила для получения лекарственных средств с действием, ингибирующим β-глюкуронидазу в ткани человека | |
CA2326720A1 (en) | Hemoglobin-haptoglobin complexes | |
RU93020151A (ru) | Способ получения препарата для направленной доставки противоопухолевых лекарств в раковую клетку |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 1007561 Country of ref document: ES |